Preparation method of pH / photo-thermal response nano-particles HMCN-coated PEI-SAA and application of pH / photo-thermal response nano-particles in drug release
By preparing pH/photothermal response nanoparticles HMCN@PEI-SAA, combined with near-infrared light and low pH environment, the problem of low drug delivery efficiency in traditional chemotherapy is solved, and a high-efficiency drug loading of the hydrophobic drug quercetin is achieved. and controlled release significantly improve the specificity and efficiency of drug delivery.
Patent Information
- Application Number
- CN202411066623.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
Traditional chemotherapy has problems with lack of specificity, prone to toxic side effects and drug resistance, and hydrophobic drugs such as quercetin are less efficient during drug delivery, making it difficult to effectively target tumor cells.
Using the preparation method of pH/photothermal response nanoparticles HMCN@PEI-SAA, the controllable drug release effect is achieved by combining mesoporous carbon nanospheres with polypeptide polymer PEI-SAA, and the controllable drug release effect is achieved through near-infrared light and low pH environment, thereby improving the drug drug delivery and delivery efficiency.
The high-efficiency drug loading and controlled release of the hydrophobic drug quercetin is achieved, which improves the specificity and efficiency of drug delivery, and significantly improves the drug release rate and accumulation rate in acidic tumor environment.
Smart Images

Figure CN118975990A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of chemical drug synthesis, and in particular to a method for preparing pH / photothermal responsive nanoparticle HMCN@PEI-SAA and its application in drug release. Background Art
[0002] Based on the drawbacks of current traditional chemotherapy (such as lack of specificity, easy to produce toxic side effects and easy to develop drug resistance), the research on stimulus-responsive drug delivery systems has attracted widespread attention. Taking advantage of the particularity of the diseased tissue environment, various active targeted drug carriers have been continuously designed and developed. Mesoporous carbon nanospheres can use the hydrophobic surface and the π-π stacking effect between the mesoporous channels and hydrophobic drugs for efficient loading; MCN has excellent photothermal conversion performance, and biological tissues have two biological penetration windows for NIR, namely the first near-infrared window (700-950nm) and the second near-infrared window (1000-1400nm). Through the combination of NIR and MCN, the light induction of NIR enhances the drug release effect of MCN, and the hydrophobic drugs can be controlled under the induction of NIR; however, when a single mesoporous carbon nanosphere carrier delivers drugs in vivo, the leakage of drugs during in vivo transportation is prone to produce cytotoxicity to normal tissue cells. Therefore, the development of stimulus-responsive mesoporous carbon nanospheres is conducive to solving this problem. Functionally modified MCN can respond to NIR stimulation and tumor cell microenvironment (such as low pH, reduced GSH, enzymes, light, electric field, etc.). Compared with endogenous stimulation, in vitro physical stimulation (light, magnetism and microwave, etc.) can easily be used as a switch to control nanocarriers. Stimulus-responsive mesoporous carbon-based nanosphere materials are gradually becoming a hot topic in the field of drug delivery system research. Quercetin (QU) is a natural flavonoid compound with strong biological activity. Studies have found that quercetin has antioxidant, anti-inflammatory, antiviral, anti-tumor, hypoglycemic and immunomodulatory effects, but QU is a hydrophobic drug with low drug delivery efficiency. Therefore, it is of great significance to design a responsive mesoporous carbon nanosphere-based drug sustained-release carrier to solve the problems of hydrophobic drug loading and controlled release.
[0003] Compared with traditional carrier materials, mesoporous carbon nanosphere-based carrier materials have the advantages of high mechanical strength, large specific surface area and good biocompatibility. Biological tissues have high permeability to NIR, and NIR causes less trauma to the human body. Carbon-based materials irradiated by NIR can effectively convert light energy into heat energy, which can induce controlled release of drugs from carrier materials in drug delivery systems. Summary of the invention
[0004] The purpose of the present invention is to prepare a pH / photothermal responsive nanoparticle HMCN@PEI-SAA and provide an application thereof in drug release.
[0005] The present invention adopts the following technical scheme: a method for preparing pH / photothermal responsive nanoparticles HMCN@PEI-SAA, preparing one unit of the particles in proportion, comprising the following steps:
[0006] Step 1, preparation of HMCN: under stirring in a water bath at 30°C, add 40mL of deionized water and 120mL of anhydrous ethanol to a three-necked flask, slowly drop 6mL, 25wt%, NH3·H2O into the system, drop 1.1mL of ethyl orthosilicate, stir until the solution is uniform, take 0.6g of resorcinol and add it to the reaction system, stir evenly, slowly drop 0.9mL, 37wt% formaldehyde, and continue the reaction for 8h; separate the precipitate by centrifugation, wash it with deionized water / ethanol for 3 times respectively, and finally vacuum dry it at 50°C. The obtained product is a phenolic resin prepolymer-silicon dioxide mixture RF@SiO2, which is carbonized in a tubular furnace in a N2 atmosphere to obtain a carbon-silicon dioxide composite, and the product is removed from the silicon-based template in 10% HF to obtain HMCNs;
[0007] Step 2: Preparation of HMCN@PEI: 0.4 g of the product from step 1 was added to 20 mL of APS solution, i.e., 2 mol·L- 1 Sulfuric acid, 0.5 mol·L- 1 In ammonium persulfate, ultrasonically homogenize and stir to react for 6 hours, centrifuge to separate the product, wash with deionized water until neutral, and dry to obtain HMCN-COOH; take 300 mg of HCNS-COOH and add it to 40 mL of deionized water, weigh 0.25 g of N-hydroxysuccinimide NHS and 0.15 g of 1-ethyl-3-dimethylaminopropylcarbodiimide EDC and add them to the reaction system, keep the water bath at a constant temperature of 35°C, stir and react for 4 hours to fully activate the carboxyl group, add 100 mg of PEI, react in a nitrogen atmosphere for 12 hours, centrifuge and wash several times, and vacuum dry to obtain HMCNS@PEI;
[0008] Step 3, preparation of HMCN@PEI-SAA: Take 0.6g of PEI-SAA and add it to a 100mL flask, add 40mL of N-dimethylformamide DMF, take NHS and EDC and add them to the reaction system, activate the reaction for 4h, and finally add HMCN@PEI, react for 12h, centrifuge to remove the supernatant, wash and dry the precipitate alternately with deionized water / anhydrous ethanol to obtain HMCN@PEI-SAA.
[0009] Furthermore, the dosage of HMCN@PEI-SAA was 15 mg, the loading temperature was 30 °C, and the initial dosing concentration was 1000 mg·L- 1 The drug loading rate was 11.74%.
[0010] Application of pH / photothermal responsive nanoparticles HMCN@PEI-SAA combined with quercetin in drug release.
[0011] Beneficial effects of the present invention: The present invention prepares a pH / photothermal responsive nanoparticle HMCN@PEI-SAA, which has good drug loading and release properties. When the dosage of HMCN@PEI-SAA is 15 mg, the drug loading temperature is 30 ° C and the initial drug concentration is 1000 mg·L- 1 When , the drug loading performance reaches a better state, and the drug loading rate is 11.74%. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 Schematic diagram of the preparation of HMCN@PEI-SAA;
[0013] Figure 2 The effect of carrier dosage on drug loading efficiency;
[0014] Figure 3 The effect of drug loading temperature on drug loading rate;
[0015] Figure 4 Effect of QU dosage on drug loading rate;
[0016] Figure 5 Standard curve of QU;
[0017] Figure 6 FT-IR images of HMCN and HMCN@PEI-SAA;
[0018] Figure 7 Electron microscopy images and particle size distribution of HMCN and HMCN@PEI-SAA;
[0019] In the figure: (a) - SEM image of HMCN; (b) - TEM image of HMCN; (c) - Particle size distribution of HMCN; (d) - SEM image of HMCN@PEI-SAA; (e) - TEM image of HMCN@PEI-SAA; (f) - Particle size distribution of HMCN@PEI-SAA
[0020] Figure 8 Potential diagrams of HMCN, HMCN-COOH, HMCN@PEI, and HMCN@PEI-SAA;
[0021] Fig. 9 Isotherm adsorption curve of HMCN@PEI-SAA;
[0022] Fig.10 Isotherm adsorption model fitting diagram of HMCN@PEI-SAA;
[0023] In the figure: (a) - Langmuir isotherm adsorption model fitting diagram; (b) - Freundlich isotherm adsorption model fitting diagram;
[0024] (c)—Fitting diagram of Temkin isotherm adsorption model; (d)—Fitting diagram of DR isotherm adsorption model
[0025] Fig.11 Kinetic fitting diagram of HMCN@PEI-SAA;
[0026] In the figure: (a) - HMCN@PEI-SAA adsorption kinetics curve; (b) - pseudo-first-order kinetic model fitting diagram;
[0027] (c)—Pseudo-second-order kinetic model fitting diagram; (d)—Intra-particle diffusion model fitting diagram
[0028] Fig.12 Drug release curve of QU@HMCN@PEI-SAA. DETAILED DESCRIPTION
[0029] Embodiment 1:
[0030] like Figure 1 The preparation process of HMCN@PEI-SAA is shown below:
[0031] 1) Preparation of HMCN
[0032] Under stirring in a 30°C water bath, add 40mL of deionized water and 120mL of anhydrous ethanol to a 250mL three-necked flask, slowly drop NH3·H2O (6mL, 25wt%) into the system, add 1.1mL of ethyl orthosilicate dropwise, stir for 20min until the solution is uniform, take 0.6g of resorcinol and add it to the reaction system. After stirring, slowly drop formaldehyde (0.9mL, 37wt%) and continue the reaction for 8h. Separate the precipitate by centrifugation, wash it with deionized water / ethanol three times respectively, and finally vacuum dry it at 50°C. The resulting product is a phenolic resin prepolymer-silica mixture (RF@SiO2), which is carbonized in a tubular furnace in a N2 atmosphere at a heating rate of 3°C·min- 1 The temperature was continuously raised to 700°C and carbonized for 4 hours to obtain a carbon-silicon dioxide composite. The product was removed from the silicon-based template in 10% HF for about 12 hours to obtain HMCNs.
[0033] 2) Preparation of HMCN@PEI
[0034] Take 0.4 g of the product and add it into 20 mL of APS solution (2 mol·L- 1 Sulfuric acid, 0.5 mol·L- 1Ammonium persulfate), ultrasonically homogenized (5 min), stirred and reacted for 6 h, centrifuged to separate the product, washed with deionized water until neutral, and dried to obtain HMCN-COOH. Take 300 mg of HCNS-COOH and add it to 40 mL of deionized water, weigh 0.25 g of N-hydroxysuccinimide (NHS) and 0.15 g of 1-ethyl-(3-dimethylaminopropylcarbodiimide) (EDC) and add them to the reaction system, keep the water bath at a constant temperature of 35 ° C, stir and react for 4 h to fully activate the carboxyl group, add 100 mg of PEI, react in a nitrogen atmosphere for 12 h, centrifuge and wash several times, and vacuum dry to obtain HMCNS@PEI.
[0035] 3) Preparation of HMCN@PEI-SAA
[0036] 0.6 g of SAA was added to a 100 mL flask, and then 40 mL of N-dimethylformamide (DMF) was added. A certain amount of NHS and EDC were added to the reaction system. The reaction was activated for 4 h, and finally HMCNs@PEI was added. The reaction was continued for 12 h, and the supernatant was removed by centrifugation. The precipitate was washed and dried alternately with deionized water and anhydrous ethanol to obtain HMCN@PEI-SAA.
[0037] Optimization of drug loading process of HMCN@PEI-SAA
[0038] 1) Effect of HMCN@PEI-SAA dosage on drug loading rate
[0039] In order to investigate the optimal dosage of HMCN@PEI-SAA for drug loading, five experimental groups were set up. The drug loading temperature was 30 °C, the concentration of QU ethanol solution was 1000 mg·L- 1 The mass of HMCN@PEI-SAA added was weighed to be 1 mg, 5 mg, 10 mg, 15 mg, and 20 mg, respectively, and the mixture was oscillated in a water bath at a constant temperature for 24 h. The drug loading rate of the sample was calculated by measuring the absorbance of the remaining drug after drug loading. Fig. 9 shown.
[0040] Depend on Figure 2 It can be seen that the increase in the carrier HMCN@PEI-SAA causes the drug loading to increase first and then decrease. When the dosage is 15.0 mg, the drug loading rate is 11.72%. The reason may be that when the carrier dosage is small, the carrier drug loading reaches saturation; the increase in the carrier dosage leads to accumulation between the carriers, resulting in an increase in the resistance of the mesoporous channels to adsorb drug molecules, which in turn leads to a corresponding decrease in the drug loading rate when the HMCN@PEI-SAA dosage is large. Therefore, the optimal dosage of HMCN@PEI-SAA in the drug loading process is 15.0 mg.
[0041] 2) Effect of drug loading temperature on drug loading rate
[0042] In order to investigate the optimal temperature for drug loading of HMCN@PEI-SAA, the experiment was carried out with a carrier dosage of 15 mg and a QU ethanol solution concentration of 1000 mg·L- 1 Under the conditions, the drug loading temperature of HMCN@PEI-SAA was set at 25-45°C, and the water bath was kept constant temperature for 24 hours. The drug loading rate of the sample was calculated by measuring the residual absorbance. Figure 3 shown.
[0043] Depend on Figure 3 It can be seen that with the increase of drug loading temperature, the drug loading first rises steadily, reaches a maximum value of 10.95% at 30℃, and then gradually decreases and stabilizes. Analysis and speculation may be due to the relatively low solubility of QU at low temperatures, and the drug molecule thermal motion is not intense. With the increase of temperature, the molecular thermal motion intensifies and the molecular diffusion is more sufficient; with the continuous increase of temperature, when the carrier is saturated with drug, the molecular thermal motion of the drug and the carrier is enhanced, the dynamic balance of adsorption is broken, the drug loading gradually decreases, and the optimal drug loading temperature is 30℃.
[0044] 3) Effect of QU dosage on drug loading rate
[0045] In order to investigate the optimal dosage of HMCN@PEI-SAA drug loading, different concentrations of QU solution (200-1200 mg·L- 1 ) and oscillate in a water bath at constant temperature for 24 h. The drug loading rate was calculated by measuring the remaining absorbance. Figure 4 shown.
[0046] Depend on Figure 4 It can be seen that with the increase of the concentration of QU ethanol solution, the drug loading rate gradually increased. 1 When the drug loading rate reaches the maximum value, it tends to be stable and the carrier adsorption capacity reaches saturation. This is because as the drug concentration increases, the carrier gradually reaches its equilibrium adsorption capacity. At this time, the drug loading rate is 11.64%. Therefore, the optimal drug loading concentration is 1000 mg·L- 1 .
[0047] Drug loading performance test of HMCN@PEI-SAA
[0048] 1) Establishment of QU standard curve
[0049] QU was selected as the model drug. 5.0 mg of QU was accurately weighed into a 50 mL brown volumetric flask and fixed to volume with anhydrous ethanol to obtain a mass concentration of 100 μg mL-1. 1 The stock solution A was diluted to obtain a mass concentration of 2.0 μg·mL- 1The drug solution was prepared with anhydrous ethanol as blank control. The detection wavelength of QU was determined by UV-1900i UV-visible spectrophotometer, and the wavelength scanning range was 300-500 nm. The QU stock solution was measured and prepared into mass concentrations of 3.0 μg·mL- 1 , 4.0μg·mL- 1 , 5.0μg·mL- 1 , 6.0μg·mL- 1 and 7.0 μg·mL- 1 A series of standard solutions, QU maximum absorption wavelength is 374nm. The fitting equation is y = 0.09411x-0.00985, R 2 is 0.9993, with a high degree of fit. Figure 5 shown.
[0050] 2) Drug loading calculation formula
[0051] The formula for calculating drug loading is as follows:
[0052]
[0053] Where:
[0054] m0—the quality of starting to deliver QU;
[0055] m1—the mass of the remaining QU of drug loading;
[0056] m2—The mass of QU@HMCN@PEI-SAA.
[0057] Structural performance test of HMCN@PEI-SAA
[0058] 1)FT-IR analysis
[0059] The infrared spectra of HMCN and HMCN@PEI-SAA were measured by the potassium bromide tablet method using the American Thermo Scientific Nicolet iS20 Fourier transform infrared spectrometer.
[0060] FT-IR analysis
[0061] The surface groups of HMCN and HMCN@PEI-SAA were characterized by FT-IR. Figure 6 shown.
[0062] Depend on Figure 6 It can be seen that in the HMCN spectrum, 3426cm- 1 is the stretching vibration peak of the phenolic hydroxyl group in HMCN; in the spectrum of HMCN@PEI-SAA, 3426cm- 1The peak enhancement is mainly due to the superposition of NH2 stretching vibration in PEI and NH stretching vibration in secondary amide, located at 1624cm- 1 The absorption peak at may be the superposition peak of CN stretching vibration and NH bending vibration in secondary amide [ 68], the absorption peak at 1726 cm-1 may be the stretching vibration of the carboxyl group in the unilaterally amidated SAA molecular structure. [ 69].
[0063] 2) SEM analysis, TEM analysis
[0064] The macrostructure of HMCN and HMCN@PEI-SAA samples was observed using S4800 SEM.
[0065] The microstructure of HMCN and HMCN@PEI-SAA was observed using the American FEI Talos F200X G2 TEM, and the electron microscope images of HMCN and HMCN@PEI-SAA were analyzed and measured.
[0066] The particle microstructures of HMCN and HMCN@PEI-SAA were analyzed by SEM and TEM. Figure 7 shown.
[0067] from Figure 7 (a) and Figure 7 As can be seen from (c), the HMCN has a regular spherical shape, an average particle size of 106.7 nm, and a relatively concentrated particle size distribution. Figure 7 In (b), the cavity structure of HMCN can be observed with clear boundaries, proving the successful preparation of hollow mesoporous carbon. Figure 7 (d) and Figure 7 In (f), it can be observed that the morphology of HMCN@PEI-SAA is spherical, and the average particle size increases to 120.2 nm. Figure 7 (e) The microscopic morphology did not change significantly, but adhesion occurred between the carriers. The boundary of HMCN@PEI-SAA became blurred, and it still had a hollow mesoporous structure. It can be inferred that the polymer modified HMCN, resulting in adhesion.
[0068] 3) Zeta potential analysis
[0069] The potentials of HMCN, HMCN-COOH, HMCN@PEI and HMCN@PEI-SAA were measured using a 90PlusPALS Zeta potential analyzer.
[0070] To determine whether the subsequent modified PEI and SAA were successfully grafted, a Zeta potential analyzer was used to analyze HMCN, HMCN-COOH,
[0071] The surface potential of HMCN@PEI and HMCN@PEI-SAA was tested and analyzed. Figure 8 shown.
[0072] from Figure 8 The analysis shows that the potential of HMCN presents a negative potential (-22.4mV) on the carrier surface due to the deprotonation of the surface phenolic hydroxyl and alcoholic hydroxyl groups. Similarly, the surface of HMCN-COOH is negatively charged (-16.9mV) because the alcoholic hydroxyl groups in HMCN are oxidized to -COOH by the oxidant, and -COOH is deprotonated to -CO O-. The surface of HMCN@PEI is positively charged (+8.2mV), which is speculated to be due to the protonation of the secondary amine group on PEI to -NH3+, and the secondary amine group and the -COOH on the carrier surface are amidated, and the combined effect is positive. After SAA modification, the carrier potential becomes negative again (-12.8mV), which may be due to the consumption of -NH2 in SAA and PEI during the amidation process, followed by the deprotonation of -COOH, which makes the surface of the carrier present a negative potential.
[0073] FT-IR results showed that HMCN@PEI-SAA was successfully prepared. Zeta potential analysis results showed that the potential difference between HMCN-COOH, HMCN@PEI and HMCN@PEI-SAA indicated that HMCN@PEI-SAA was successfully prepared. SEM and TEM showed that HMCN and HMCN@PEI-SAA were uniform nanoparticles, and the average particle size increased from about 106.7 nm to about 120.2 nm before and after modification.
[0074] Study on adsorption thermodynamic properties and mechanism
[0075] In order to investigate the adsorption performance and mechanism of HMCN@PEI-SAA for model drugs and explore the relationship between the equilibrium adsorption amount of HMCN@PEI-SAA and drug concentration, the model and fitting results are shown in Fig. 9 , Fig.10 And as shown in Table 1.
[0076] Depend on Fig. 9 It can be seen that when the QU concentration is 200~1200mg·L- 1 In the range of 1000 mg·L- 1 When the adsorption capacity reaches the maximum and tends to be stable, it reaches 133.3 mg·L- 1 ,This phenomenon is mainly because when the drug concentration is low, the adsorption sites of the carrier are sufficient, and when the model drug concentration reaches a certain value, the adsorption sites of the carrier are saturated.
[0077] The Langmuir, Freundlich, Temkin and DR models were used to fit the thermodynamic curves and explore the adsorption mechanism of HMCN@PEI-SAA. Fig.10 The information in Table 1 shows that the fitting degree of the Langmuir isotherm adsorption equation is better than that of the other three models, and R 2 It is higher (0.961), indicating that the adsorption mechanism of HMCN@PEI-SAA is more consistent with the Langmuir equation. It can be inferred that the adsorption of HMCN@PEI-SAA is mainly monolayer adsorption.
[0078] Table 1 Adsorption thermodynamic parameters of HMCN@PEI-SAA
[0079]
[0080] Adsorption kinetics and mechanism studies
[0081] According to the relationship between the adsorption performance and adsorption time of HMCN@PEI-SAA, an adsorption kinetic model was established. The results are shown in Fig.11 and Table 2.
[0082] from Fig.11 As can be seen from (a), the adsorption amount of HMCN@PEI-SAA gradually increases with time. In the adsorption time of 0-240 min, the adsorption rate of HMCN@PEI-SAA remains in a high range, which may be caused by the physical adsorption of the carrier mesopores. In the range of 240-1440 min, the adsorption rate of the carrier slows down and basically maintains a stable adsorption rate. In the range of 1440-1560 min, the adsorption amount of the carrier remains basically unchanged, reaching a maximum adsorption amount of 121.68 mg·g- 1 In order to further explore the adsorption mechanism of the carrier, the kinetic model was used to fit the carrier. The results are as follows: Fig.11 (b), (c), (d) and Table 2.
[0083] As can be seen from Table 2, the R 2 They are 0.967, 0.991 and 0.955 respectively. It can be inferred that the adsorption process of HMCN@PEI-SAA on QU is more in line with pseudo-second-order kinetics. At the same time, the different adsorption rates shown in the kinetic adsorption curves indicate that the adsorption process of QU on the carrier is a joint process of physical adsorption and chemical adsorption.
[0084] Table 2 Adsorption kinetic parameters of HMCN@PEI-SAA
[0085]
[0086] To explore the effects of pH and NIR irradiation on the drug release performance of HMCN@PEI-SAA, the drug release efficiency of QU@HMCN@PEI0-SAA at 808 nm and pH 6.0 and 7.4 was investigated. Fig.12 As shown. Fig.12 It can be seen that the overall cumulative drug release rate of the carrier QU@HMCN@PEI-SAA in the environment of simulated normal tissue fluid (pH = 7.4) is low, and the cumulative drug release rate of 48h is 10.4%. This is mainly due to the fact that the amine and carboxylic acid amide bonds in the low molecular weight PEI are relatively stable in a neutral environment, and the blocking effect on the pores leads to a low drug release rate. Under the conditions of simulated tumor environment tissue fluid (pH = 6.0), the drug release rate rises rapidly within 0-8h, and the cumulative release rate of 48h is 11.9%, which is generally better than the carrier release under neutral conditions. This is because under acidic conditions, the protonation of -NH2 on PEI enhances the intermolecular electrostatic repulsion and weakens the blocking effect of the modified layer on the carrier pores. Therefore, it can be inferred that HMCN@PEI-SAA has certain pH response performance. By irradiating the experimental groups with pH values of 6.0 and 7.4 at release times of 4h, 8h and 12h, respectively, it can be found that at the same pH, the cumulative drug release rate of the experimental group after NIR irradiation was significantly accelerated. The CRP of the experimental group with pH = 6.0 + NIR at 48h was 15.1%, and the CRP of the experimental group with pH = 7.4 + NIR at 48h was 12.6%, both of which were higher than the experimental group without NIR application. The reason may be that the carrier undergoes photothermal conversion on its surface in an acidic environment and under NIR irradiation, which causes the carrier temperature to rise, intensifies the thermal motion of surface groups and drug molecules in the pores, and makes it easier for the drug molecules to diffuse into the medium. It can be inferred that HMCN@PEI-SAA has photothermal controllability.
Claims
1. Preparation method of pH / photothermal responsive nanoparticles HMCN@PEI-SAA, characterized in that: The method of preparing one unit of the granules in proportion comprises the following steps: Step 1, preparation of HMCN: under stirring in a water bath at 30 ° C, add 40 mL of deionized water and 120 mL of anhydrous ethanol to a three-necked flask, slowly drop 6 mL, 25 wt%, NH3·H2O into the system, add 1.1 mL of ethyl orthosilicate dropwise, stir until the solution is uniform, take 0.6 g of resorcinol and add it to the reaction system, stir evenly, slowly drop 0.9 mL, 37 wt% formaldehyde, and continue to react for 8 h; separate the precipitate by centrifugation, wash it with deionized water / ethanol for 3 times respectively, and finally vacuum dry it at 50 ° C. The obtained product is a phenolic resin prepolymer-silica mixture RF@SiO2, which is carbonized in a tubular furnace in a N2 atmosphere to obtain a carbon-silica composite, and the product is removed from the silicon-based template in 10% HF to obtain HMCNs; Step 2: Preparation of HMCN@PEI: Take 0.4 g of the product from step 1 and add it to 20 mL of APS solution, i.e., 2 mol·L -1 Sulfuric acid, 0.5 mol·L -1 In ammonium persulfate, after ultrasonic homogenization, stirring and reacting for 6 h, the product was separated by centrifugation, washed with deionized water until neutral, and dried to obtain HMCN-COOH; 300 mg of HCNS-COOH was added to 40 mL of deionized water, 0.25 g of N-hydroxysuccinimide NHS and 0.15 g of 1-ethyl-3-dimethylaminopropylcarbodiimide EDC were weighed and added to the reaction system, the water bath was kept at a constant temperature of 35 °C, and the reaction was continued for 4 h with stirring to fully activate the carboxyl group, 100 mg of PEI was added, and the reaction was carried out in a nitrogen atmosphere for 12 h, centrifuged and washed several times, and vacuum dried to obtain HMCNS@PEI; Step 3. Preparation of HMCN@PEI-SAA: Take 0.6 g of PEI-SAA and add it to a 100 mL flask, add 40 mL of N-dimethylformamide (DMF), take NHS and EDC and add them to the reaction system, activate the reaction for 4 h, and finally add HMCNs@PEI, react for 12 h, centrifuge to remove the supernatant, wash and dry the precipitate alternately with deionized water / anhydrous ethanol to obtain HMCNs@PEI-SAA.
2. The method for preparing pH / photothermal responsive nanoparticles HMCN@PEI-SAA according to claim 1, characterized in that: The dosage of HMCN@PEI-SAA was 15 mg, the loading temperature was 30 °C, and the initial dosage concentration was 1000 mg·L -1 The drug loading rate was 11.74%.
3. Application of pH / photothermal responsive nanoparticles HMCN@PEI-SAA combined with quercetin in drug release.
Citation Information
Cited By
Maize germ exosome extraction method, exosome preparation and application
CN121910889A
